Anticoagulants.
D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001791:Blood Platelet Disorders / Q000188:drug therapy; D004176:Dipyridamole / Q000627:therapeutic use; D057487:Enzyme Therapy; D005164:Factor IX / Q000032:analysis; D005167:Factor VII / Q000032:analysis; D005170:Factor X / Q000032:analysis; D006460:Hemolysin Proteins / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006494:Heparin Antagonists; D006801:Humans; D007263:Infusions, Parenteral; D010630:Phenindione / Q000627:therapeutic use; D011479:Protamines / Q000494:pharmacology; D011516:Prothrombin / Q000032:analysis; D013300:Streptokinase / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000517:prevention & control; D013927:Thrombosis / Q000188:drug therapy*; D014688:Venoms; D014859:Warfarin / Q000494:pharmacology / Q000627:therapeutic use
D000925:Anticoagulants; D006460:Hemolysin Proteins; D006494:Heparin Antagonists; D011479:Protamines; D014688:Venoms; D010630:Phenindione; D014859:Warfarin; D004176:Dipyridamole; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; D006493:Heparin; D013300:Streptokinase; D001241:Aspirin; D013442:Sulfinpyrazone